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Uveal melanoma (UM) is the most common intraocular
tumor in adults. Nearly half of UM patients develop metastatic
disease and often succumb within months because effective
therapy is lacking. A novel therapeutic approach has been
suggested by the discovery that UM cell lines driven by mutant
constitutively active Gq or G11 can be targeted by FR900359
(FR) or YM-254890, which are bioavailable, selective inhibitors
of the Gq/11/14 subfamily of heterotrimeric G proteins. Here,
we have addressed the therapeutic potential of FR for UM. We
found that FR inhibited all oncogenic Gq/11 mutants reported
in UM. FR arrested growth of all Gq/11-driven UM cell lines
tested, but induced apoptosis only in a few. Similarly, FR
inhibited growth of, but did not efficiently kill, UM tumor cells
from biopsies of primary or metastatic tumors. FR evoked
melanocytic redifferentiation of UM tumor cells with low
(class 1), but not high (class 2), metastatic potential. FR
administered systemically below its LD50 strongly inhibited
growth of PDX-derived class 1 and class 2 UM tumors in
mouse xenograft models and reduced blood pressure tran-
siently. FR did not regress xenografted UM tumors or signifi-
cantly affect heart rate, liver function, hematopoiesis, or
behavior. These results indicated the existence of a therapeutic
window in which FR can be explored for treating UM
and potentially other diseases caused by constitutively active
Gq/11.
Mutant constitutively active forms of Gq or G11 (Gq/11)
α-subunits of heterotrimeric G proteins cause uveal mela-
noma (UM) (1–3) and several other diseases and disorders
(4–11). UM is particularly devastating because patients with
metastatic disease often succumb within months due to lack
of effective therapy (12). Clinical trials of metastatic UM have
shown little benefit of cytotoxic chemotherapeutics, immune
checkpoint inhibitors, or small-molecule inhibitors of onco-
genic signaling proteins including protein kinase C and MEK
(13). New therapeutic strategies for metastatic UM clearly are
warranted.
Recent evidence suggests that mutant constitutively active
Gq/11 could be targeted therapeutically in UM and other
diseases (14). Oncogenic Gq/11 α-subunits are constitutively
active due to defects in hydrolyzing GTP to GDP, the rate-
limiting step for G protein deactivation. Nevertheless, onco-
genic Gq/11 can be inhibited by FR900359 (FR) or YM-254890
(YM) (15–20), a pair of closely related, bioavailable cyclic
depsipeptides that allosterically inhibit GDP release by the Gq/
11/14 subfamily (16, 21). Inhibition is thought to occur
because oncogenic Gq/11 α-subunits can spontaneously
release GTP, stochastically bind GDP, bind YM or FR (YM/FR)
and Gβγ subunits (17), forming complexes resistant to acti-
vation by G-protein-coupled receptors (14, 16) and diminish-
ing downstream oncogenic signaling (17–20). In response to
YM/FR, UM cell lines driven by oncogenic Gq/11 arrest the
cell cycle and can undergo apoptosis and/or redifferentiation
into melanocytic-like cells (17–20). In contrast, BRAF-driven
UM cell lines, which express wild-type Gq/11, are unaffected
(17–20).
The therapeutic potential of YM/FR in UM is an important
opportunity based on this evidence. Critical issues and ques-
tions remain to be addressed, however. YM/FR may exert
deleterious as well as therapeutically beneficial effects, because
they do not discriminate between wild-type and oncogenic
Gq/11 (14), and target Gq/11-dependent physiological systems
(21–24) essential for homeostasis and viability (25–28).
Indeed, YM/FR administered systemically at levels that reduce
Gq/11 activity in host systems greater than 50% is likely to be
lethal, as suggested by gene dosage studies of Gq/11 knockout
mice (29). Indeed, how strongly oncogenic Gq/11 signaling in
UM tumors must be inhibited for therapeutic effect remains
unknown. Furthermore, although recent studies have shown
that YM/FR can inhibit growth of UM tumors in mouse
xenograft models (19, 30), questions left unanswered are
whether YM/FR can target primary and/or metastatic UM
tumor cells from patients, whether YM/FR responsiveness is
affected by tumor-intrinsic factors, including the type of
oncogenic Gq/11 mutation, tumor class or metastatic poten-
tial, or whether systemic administration of YM/FR at levels
sufficient to target UM tumor xenografts has serious
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deleterious effects on viability or host physiological systems.
Here, we have addressed all of these important issues.
Results
FR inhibits all oncogenic Gq and G11 mutants that drive uveal
melanoma
At least ten different constitutively active Gq/11 mutants
have been identified in UM (2, 31, 32). Only four had been
studied previously and shown to be inhibited by FR or YM
(17–20). To extend this analysis, we transiently expressed
each of ten different Gq/11 mutants that drive UM (Fig. 1A)
with a Gq/11-driven transcriptional reporter in a common
cellular context (HEK293 cells) to exclude extrinsic factors
that might affect the results. We found that each mutant
G protein induced reporter expression and was inhibited
by FR with similar potency (IC50 1.9–3.8 nM) and efficacy
(Fig. 1A).
In contrast, we found that four UM cell lines (Fig. 1B)
driven by three different oncogenic Gq/11 mutants
responded to FR in quantitatively or qualitatively different
ways. FR inhibited growth of all four Gq/11-driven UM cell
lines, but with potencies differing by as much as 80-fold
(IC50 0.5 nM (MP41 cells), 38 nM (Mel270 cells); Fig. 1B).
Whereas FR arrested the cell cycle of all Gq/11-driven UM
cell lines, as indicated by reduction of S- and G2/M-phase
cells (Figs. 1C and S1), it induced significant apoptosis
only in two of them (92.1 and Mel270 cells), as indicated by
accumulation of cells with sub-G0/G1 DNA content
(Figs. 1C and S1). FR did not affect proliferation or survival
of a BRAF(V600E)-driven UM cell line (Fig. 1B), as shown
Figure 1. Effects of FR on constitutively active Gq/11 mutants and UM cell lines. A, effects of FR on expression of an SRE.L reporter driven by
transfection of oncogenic Gq/11 mutants in HEK293 cells. FR inhibited all ten Gq/11 mutants reported in UM, with IC50s between 1.9 nM (Gq-Q209 L) and
3.8 nM (Gq-R183Q). Representative means and SEMs were calculated from triplicate values from one of at least three independent experiments for each
mutant. B, effects of FR on UM cell lines. Growth of UM cell lines driven by constitutively active Gq or G11 mutants was inhibited by FR with IC50s between
0.5 nM (MP41) and 38 nM (Mel270). A UM cell line (OCM-1A) driven by constitutively active BRAF(V600E) was unaffected by FR. Representative means and
SEMs were calculated from triplicate values from one of at least three independent experiments for each cell line. C, effect of FR on apoptosis and cell cycle
progression of UM cell lines analyzed by flow cytometry. Induction of apoptosis was indicated by increased proportion of cells with sub-G1/G0 DNA content.
Cell cycle arrest was indicated by decreased proportion of cells with S- and G2/M-phase DNA content. Representative means and SEMs calculated from
triplicate values from one of at least three independent experiments for each cell line.
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before (17–19), demonstrating the selectivity of FR for
oncogenic Gq/11 in UM.
FR redifferentiates class 1 but not class 2 UM cells
Class 1 and class 2 primary UM tumors have low (5%) and
high (90%) probability of metastasis, respectively (33, 34).
Class 1 UM tumors express the metastasis suppressor, BAP1,
encoding an enzyme that regulates gene expression epigenet-
ically by deubiquitinating histone H2A. Class 2 UM tumors are
BAP1-deficient (35) and possess additional genetic defects
rendering them prone to metastasis (32). Almost all UM cell
lines are derived from class 1 tumors (36), raising the crucial
question of whether both classes of primary UM tumor cells
can be targeted by FR.
We addressed this question initially by analyzing MP41
(class 1; BAP1+) and MP46 (class 2; BAP1-deficient) cell lines,
which were established originally from patient-derived xeno-
grafts (PDX) of primary UM tumors (37). We found that FR
arrested growth and cell cycle progression of both of these cell
lines without triggering significant apoptosis (Fig. 1, B and C).
Next, we used transcriptional analysis to determine whether
FR could redifferentiate MP41 (class 1) and MP46 (class 2)
cells into melanocytic-like cells, as we had shown previously
with two other class 1 UM cell lines (92.1 and Mel202) (17).
MP41 and MP46 cells both responded transcriptionally to FR,
as indicated by multidimensional scaling analysis of RNAseq
data (Fig. 2A). However, a cluster of genes was downregulated
preferentially in class 1 MP41 cells (circled in Fig. 2B), as
Figure 2. Transcriptional responses elicited by FR in UM cell lines that model class 1 and class 2 tumors. A, multidimensional scaling plot of RNAseq
data showing similar directional responses of MP41 (class 1) and MP46 (class 2) cells to FR. Two independent experiments were performed for each cell line.
B, Scatter plot comparing the effects of FR on gene-by-gene basis in MP41 and MP46 cells. Each blue dot represents a single gene. Genes circled in red were
downregulated (log2 fold change < -2.5) by FR significantly more strongly in MP41 (mean p = 0.04 for 365 genes) cells relative to MP46 cells (mean
p = 0.17 for 365 genes). C, gene-set enrichment analysis of genes preferentially downregulated by FR in MP41 cells (log-rank t-tests). Red arrows indicate
PRC2-targeted gene sets. D, gene-set enrichment analysis indicating the effects of FR on expression of PRC2-targeted genes in MP41 and MP46 cells.
Representative images of pelleted cells (lower panels) demonstrating the effects of FR on pigmentation as a marker of melanocytic differentiation of
MP41 and MP46 cells.
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revealed by analyzing transcriptional responses on a gene-by-
gene basis. We defined this cluster as genes with log2 fold
change in MP41 cells < -2.5 in response to FR, which iden-
tified 365 genes that were more significantly downregulated in
MP41 cells (mean p = 0.04) than MP46 cells (mean p = 0.17).
Many genes in this cluster are targets of epigenetic regulation
by polycomb repressive complex 2 (PRC2), based on gene set
analysis (H3K27trimethylation, EZH2; Fig. 2C). This PRC2-
targeted gene cluster was coordinately repressed by FR in
class 1 MP41 cells as compared with class 2 MP46 cells
(Fig. 2D). Consistent with these distinctions, FR induced
pigmentation, a hallmark of melanocytic differentiation, of
MP41 but not MP46 cells (Fig. 2D). Indeed, our prior studies
had shown that PRC2 activity is required for FR to reinstate
melanocytic differentiation of two other class 1 UM cell lines
(92.1 and Mel202) (17). Therefore, the ability of FR to promote
melanocytic redifferentiation of primary UM tumors may
depend on tumor class.
FR targets UM cells from primary and metastatic tumors
Because UM tumor cell lines do not fully recapitulate
important properties of UM tumors, we determined whether
FR can target UM cells obtained from patient biopsies of
primary and metastatic tumors. We began by preparing
Figure 3. Response of human UM tumor biopsy samples to FR ex vivo. A, effects of FR on cell abundance in self-renewing cultures from UM patient
biopsies. Human tumor fine-needle biopsy samples of the indicated UM tumors were established in culture and split equally. Cells were counted after
7 days of culture upon treatment with vehicle or FR (100 nM). Each bar indicates an individual tumor sample. B, effect of FR on total RNA yield from UM
patient biopsies. The indicated human UM biopsy samples from class 1 and class 2 primary UM tumors and a liver metastasis were dissociated, split equally,
and treated immediately for 7 days with vehicle or FR (100 nM). The effect of FR relative to vehicle controls on the yield of total RNA as a marker of cell
number is shown. Each bar indicates an individual tumor sample. One biopsy sample (UM032) expressed wildtype Gq and G11 and was unaffected by FR. In
panels A and B, class 1 tumor samples are blue; class 2 tumor samples are red; metastatic tumor sample is gray. C, effect of FR on global gene expression in
freshly isolated UM biopsies detected by RNAseq. Principal component analysis (PCA) of RNAseq data from class 1 (including the Gq/11-wild-type sample:
WT) and class 2 (including metastatic sample: MM) human tumor biopsy samples. Arrows indicate the directional effect of FR on gene expression for each
biopsy sample. D, combined PCA analysis of the effects of FR on gene expression in UM biopsy samples shown in panel C. Class 1 tumor samples are blue;
class 2 tumor samples are red; metastatic tumor sample is gray; unresponsive wild-type Gq/G11 sample (UM032) is green. Correlations of principal
component 1 (x-axis) and principal component 3 (z-axis) with FR-treatment were significant (paired t-tests with Holm–Sídák correction, p < 0.01: **).
E, FR elicits transcriptional responses in UM tumor but not stromal cells as detected by single-cell RNAseq. Two-dimensional t-SNE plots of single-cell
scRNAseq data are shown for each of the three indicated primary UM tumor samples obtained after enucleation, and treated 7 days with vehicle or FR
(100 nM). Individual cell types are color coded in each panel. t-SNE plots of data obtained after vehicle (left panel) and FR (right panel) treatment of the
indicated tumor samples are shown. The transcriptional profile of melanoma cells from a given tumor overlap little in vehicle- and FR-treated samples,
indicating marked transcriptional response to FR. The transcriptional profile of each nonmelanoma cell type from a given tumor overlap extensively in
vehicle- and FR-treated samples, indicating little transcriptional response to FR.
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separate self-renewing cultures of UM tumor cells isolated
from fine-needle biopsies of class 1 primary tumors from six
patients and core biopsies of liver metastases from two
patients. We found that all eight individually cultured-cell
samples responded to FR, as indicated by lower cell numbers
relative to vehicle controls (Fig. 3A), and we noted, as shown
before (36, 37), that class 2 primary UM tumor samples
proliferated too poorly in vitro to establish self-renewing cul-
tures. Accordingly, each time thereafter we obtained biopsy
samples from additional patients, we prepared short-term
cultures and analyzed the effects of FR. A total of ten biopsy
samples (Table S1), including class 1 and class 2 primary tu-
mors and a liver metastasis, were analyzed. Cultured cells from
nine of these patient samples responded to FR relative to
vehicle controls, as indicated by decreased yields of total RNA
as a marker of cell number (Fig. 3B). The single nonresponding
sample (UM032; Fig. 3B) expressed wild-type Gq and G11
(Table S1) and thus was driven by other oncogenes whose
identities were not determined. For the nine FR-responsive
UM tumor samples, which included class 1 and class 2 pri-
mary tumors and a liver metastasis, we found that FR caused
similar directional effects on gene expression, as revealed by
unsupervised principal component analysis (PCA) (Fig. 3C).
Interestingly, the principal component that distinguished class
1 from class 2 and metastatic tumor cells (Fig. 3D; y-axis) (33)
was relatively unaffected by FR (Fig. 3D), suggesting that FR
did not cause class 2 UM tumor samples to lose their class
identity and become more class 1-like. The one UM tumor
sample that expressed wild-type Gq and G11 did not show
significant directional effects of FR on gene expression
(Fig. 3C). Together, these results demonstrated that, regardless
of tumor class, primary and metastatic UM tumor samples
driven by mutant Gq/11 responded ex vivo to FR.
Because patient-derived UM tumor biopsies include cancer
and stromal cells, we determined which cell types were tar-
geted by FR, as indicated by their relative abundance and
transcriptional responses revealed by single-cell RNAseq
(scRNAseq). Primary tumor samples from three UM patients
undergoing enucleation were used to obtain sufficient
quantity of cells for these experiments. Dissociated UM tu-
mor and stromal cells were treated 7 days with FR at a con-
centration (100 nM) that strongly inhibited all oncogenic Gq/
11 mutants (Fig. 1A). Transcriptional signatures readily
distinguished UM cells from stromal cell types (Fig. 3E). In all
three biopsy samples, FR modestly reduced the abundance of
UM cells and had little effect on the abundance of non-UM
cells (Fig. 3E). FR therefore did not cause extensive death of
UM cells.
Further analysis of scRNAseq data indicated that UM cells,
but not stromal cells, displayed striking transcriptional re-
sponses to FR. As visualized by t-SNE plots of scRNAseq data
(Fig. 3E), FR dramatically shifted the transcriptional profile of
UM cells in all three biopsy samples. These changes in UM
gene expression in tumor samples from enucleated patients
were analogous to those observed previously by bulk RNAseq
of small biopsy samples (Fig. 3D). In contrast, FR did not
significantly affect the transcriptional profiles of stromal cells
in all three biopsy samples (Fig. 3E). UM tumor cells therefore
were targeted transcriptionally by FR.
Transcriptional analysis also indicated that FR inhibited cell
cycle progression of patient-derived UM tumor cells. FR-
evoked changes in gene expression detected by scRNAseq in
UM cells from enucleated tumors and bulk RNAseq of small
biopsies were similar, as shown by hallmark enrichment
analysis (Fig. 4A). In both cases, targets of E2F transcription
factors (arrows in Fig. 4, A and B) were among the gene sets
prominently downregulated by FR. Moreover, FR treatment of
class 1 and class 2 biopsy samples downregulated expression of
the E2F transcription factors E2F1, E2F2, and E2F8 (Fig. 4C)
and upregulated expression of the cell cycle inhibitors RB1 and
p130 (38). In sum, inhibition of oncogenic Gq/11 by FR
upregulated Rb expression and downregulated E2F expression,
thereby contributing to inhibition of UM cell cycle progression
(Fig. 4D).
Next, we investigated whether tumor class, which predicts
metastatic potential and patient prognosis, determines
whether FR evokes melanocytic redifferentiation of UM tumor
cells in patient biopsies, as we had observed above with UM
cell lines (Fig. 2). When we examined transcriptional responses
of patient-derived class 1 UM tumor cells to FR, we found
strong enrichment of gene sets targeted by PRC2 (Fig. 4E).
Nearly all members of the FR-responsive PRC2-targeted gene
cluster that were identified in UM cell lines (Fig. 2) were also
downregulated in class 1 UM tumor biopsies (Fig. 4F). In
contrast, many of these genes were upregulated, rather than
downregulated by FR in class 2 UM tumor biopsies (Fig. 4F).
Furthermore, melanocyte differentiation genes, including
MITF, TYR, and TYRP1, were upregulated significantly by FR
in class 1 relative to class 2 tumor biopsy samples (Fig. 4G).
Therefore, FR treatment potentially could inhibit progression
of class 1 primary UM tumors by promoting melanocytic
redifferentiation.
FR up- and downregulates YAP1-driven genes
Prior studies of UM have shown that oncogenic Gq/11
signaling leads to activation of the YAP1 transcription factor
(19, 20). We therefore determined whether YAP-targeted
genes are coordinately downregulated by FR in biopsy sam-
ples of class 1 and class 2 primary UM tumors. In contrast to
this expectation, we found that FR upregulated and down-
regulated YAP-targeted genes in nearly equal proportion
(Fig. S2). The mechanisms responsible for the complex effects
of FR on YAP-targeted genes are unknown, but potentially
involve the combinatorial actions of other transcription factors
with YAP1 on the promoters of these genes.
A therapeutic window for targeting UM tumors with FR
Because inhibition of Gq/11 activity by more than 50% is
likely to be lethal, as indicated by gene dosage studies in
knockout mice (29), we sought to define protocols and con-
ditions under which chronic, systemic administration of FR is
physiologically tolerated, so we could assess the therapeutic
potential of FR in mouse xenograft models of UM. Based on
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Figure 4. Pathway analysis of FR-induced transcriptional responses in UM. A, hallmark gene-set enrichment analysis of differential gene expression in
response to FR. Left panel shows gene sets affected by FR in enucleation-derived UM cells identified by scRNAseq. Right panel shows gene sets affected by
FR in nine biopsy samples described in Figure 3 as detected by RNAseq. Red arrow indicates that E2F target genes were significantly downregulated in both
scRNAseq and bulk RNAseq datasets. B, enrichment plot of the E2F target hallmark gene set detected by bulk RNAseq. Heatmap below shows insignificant
difference in response of this gene set to FR in class 1 versus class 2 biopsy samples. C, effects of FR on expression of Rb/E2F family members in class 1 and
class 2 biopsy samples detected by RNAseq (p107:RBL1; p130:RBL2). Asterisks indicate significant effect (p < 0.01; paired t-test) relative to vehicle controls.
Differences between class 1 and class 2 samples were insignificant. D, proposed model for cell cycle regulation by constitutively active Gq/11 and FR.
Signaling by constitutively active Gq/11 leads to repression of Rb expression and induction of E2F expression that drives UM cell proliferation. FR attenuates
these effects to arrest cell cycle progression. E, differential responses of class 1 and class 2 tumor biopsy samples to FR. Gene-set enrichment analysis
identifies genes downregulated preferentially in class 1 relative to class 2 tumor biopsy samples (log-rank t-test). Red arrows indicate PRC2-specific gene
sets. F, heat map showing effects of FR on PRC2-targeted genes in class 1 versus class 2 tumor samples. G, responses of melanocytic differentiation genes to
FR in class 1 and class 2 tumor biopsy samples. Asterisks indicate statistically significant (p < 0.01; paired t-test) effects of FR on the indicated melanocytic
differentiation genes in class 1 and class 2 biopsy samples.
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prior studies examining the acute effects of FR or the closely
related inhibitor YM-254890 (YM) (22, 24, 39), we adminis-
tered FR by subcutaneous injection at 0.1–3.0 mg/kg on
alternate days for 30 days to define an LD50 of 0.6 mg/kg in
NOD-scid-gamma (NSG) mice used as xenograft recipients
(Fig. 5A). We then determined the effect of FR administered
chronically below its LD50 (0.1 or 0.3 mg/kg by subcutaneous
injection on alternate days) on several physiological parame-
ters of NSG mice. Blood pressure, a sensitive indicator of Gq/
11 activity (40), decreased significantly in conscious mice upon
each injection of FR relative to vehicle controls (Fig. 5B), but
rebounded to baseline within 24 h (Fig. 5C). Heart rate was
affected insignificantly by FR (Fig. 5B). No evidence of anemia,
monocyte or platelet deficiency (Table S2), or liver disfunction
(Fig. 5D) was observed after treating NSG mice 30 days with
FR at either dose relative to vehicle controls. Lastly, when
administered for 1 week at the higher dose, FR had insignifi-
cant effect on the activity, exploratory behavior, or sensori-
motor function of NSG mice (Table 1 and Fig. S3), even
though Gq/11 are important regulators of nervous system
Figure 5. Effects of systemically administered FR on mouse viability and physiology. A, survival analysis. NSG mice were treated up to 30 days by s.c.
injection of vehicle or FR at the indicated doses on alternate days (vehicle, n = 34 mice; FR 0.1 mg/kg, n = 22 mice; FR 0.3 mg/kg, n = 22 mice; FR 1.0 mg/kg,
n = 10 mice; FR 3.0 mg/kg, n = 13 mice). Kaplan–Meier (upper panel) and survival (lower panel) curves indicate an LD50 of 0.6 mg/kg. B, effect of FR on
blood pressure as an indicator of Gq/11 inhibition in host systems. Adult male NSG mice received subcutaneous administration of vehicle (2 μl DMSO in
200 μl of 5% dextrose, saline; n = 7 mice) or FR (0.3 mg/kg, n = 9 mice) once every other day for 14 days. Blood pressure and heart rate were monitored
telemetrically 1 h before and 3 h after injection. Injection times are indicated by green arrows. Days without radiotelemetry recording or injection are
indicated by gray columns. C, twenty-four-hour continuous radiotelemetry recordings of blood pressure and heart rate in mice before the start of the
injection regimen (baseline, black line, n = 16 mice) and after the first (blue line, n = 9 mice) and seventh injections (red line, n = 7 mice), respectively. The
shaded regions represent 12 h dark periods, while the green arrows indicate the time of injection. All values are mean ± SEM. Blood pressure (BP) and heart
rate (HR) values are plotted at 1 h intervals. D, Effect of FR liver function. Blood samples were collected from mice after 30 days of treatment with vehicle or
FR (s.c. on alternate days; n = 10 mice per group) and assayed for liver enzyme activities. No significant changes were seen with FR treatment. DBP, diastolic
blood pressure; HR, heart rate; MBP, mean blood pressure; SBP, systolic blood pressure.
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development and activity (40). Chronic systemic administra-
tion of FR below its LD50 therefore had modest or undetect-
able effects on physiological systems that potentially could
limit dosing regimens in UM clinical trials.
Next, we determined whether FR delivered systemically at
physiologically tolerated doses could inhibit growth of xeno-
grafted UM tumors driven specifically by oncogenic Gq/11.
These experiments used MP41 and MP46 cells, for several
reasons. These UM cell lines were isolated originally from
patient-derived xenografts, provide models of class 1 and class
2 tumors, and, of the UM cell lines tested, responded to FR
(cell cycle arrest, with little or no apoptosis) most like UM
tumor cells from patient biopsies. We also used a UM cell line
(OCM-1A) driven by BRAF(V600E) to determine whether
effects of FR were specific for Gq/11-driven tumors. Accord-
ingly, subcutaneous UM tumor xenografts of MP41, MP46,
and OCM-1A cells were established, and vehicle or FR
was administered systemically at low (0.1 mg/kg) or high
(0.3 mg/kg) dose on alternate days by subcutaneous injection
on the contralateral side. Tumor size was measured over time
and tumor weight was determined at the end of the experi-
ment. Relative to vehicle controls, overall survival of tumor-
bearing mice treated 30 days with FR at low or high dose
was respectively 85% and 71%. Under these conditions, FR
inhibited growth of MP41 tumors only at the high dose
(Fig. 6A), but inhibited growth of MP46 tumors at either dose
(Fig. 6A). FR had no effect on growth of BRAF(V600E)-driven
OCM-1A tumors (Fig. 6A), demonstrating that FR did not
affect processes such as tumor vascularization or perfusion
that generically support tumor growth. Thus, FR specifically
targeted both class 1 and 2 UM tumor xenografts, but only
those driven specifically by oncogenic Gq/11.
To determine the extent to which FR delivered systemically
at a therapeutically effective dose inhibited oncogenic G pro-
tein signaling in vivo, we compared the effects of FR on Erk
activity, one of several downstream pathways activated by
oncogenic Gq/11 in UM (41), in vitro vs. in vivo (Figs. 6B and
S4). We used MP41 cells and tumors because, in the absence
of FR, phosphorylated Erk was detected readily and repro-
ducibly in vitro and in vivo, as compared with MP46 cells and
tumors. As a reference for in vivo studies, we first determined
the maximal extent that Erk phosphorylation in MP41 cells
was inhibited by FR in vitro. At concentration of FR (1 μM)
that maximally suppressed reporter activity driven by onco-
genic Gq or G11 (Fig. 1A), Erk phosphorylation in MP41 cells
was reduced in vitro by 85% (Figs. 6B and S4). In contrast, FR
administered in vivo at a therapeutically effective dose
(0.3 mg/kg on alternate days) for 26 days reduced Erk phos-
phorylation in G11-driven MP41 tumors in vivo by only 30%
(Figs. 6B and S4). Thus, modulation rather than complete
suppression of oncogenic G protein signaling in MP41 tumor
xenografts was sufficient for FR to have therapeutic effect.
Lastly, we investigated whether FR caused durable arrest
or regression of class 1 UM tumor xenografts. In this
experiment, mice were implanted with MP41 cells and
allowed to form tumors. MP46 tumors were not studied
because their slow growth made it difficult to determine
whether FR potentially caused durable arrest or regression.
We arrested MP41 tumor growth by treating animals with FR
at an effective dose (0.3 mg/kg s.c. on alternate days) for
25 days (Fig. 6C). FR treatment then was stopped. Tumors
resumed growth 16 days later (Fig. 6C). Therefore, FR
appeared to cause reversible rather than durable arrest or
regression of MP41 tumors. Taken together, these results
indicated the existence of a therapeutic window in which FR
effectively targeted class 1 or class 2 UM tumor xenografts,
while preserving sufficient function of Gq/11 in host tissues
required to support essential physiological processes and
viability.
Discussion
Targeting UM tumors with FR
Here we have provided several new lines of evidence that
support the therapeutic potential of Gq/11 inhibitors such as
FR for UM. Our findings indicate that the vast majority of
primary and metastatic UM tumors potentially can be targeted
by FR. We found that all constitutively active mutant forms of
Gq/11 found in UM, which collectively drive tumorigenesis in
>90% of patients, are sensitive to FR. Moreover, FR can target
Table 1
Effect of FR on mouse behavior
Variable CTL mean TX mean Diff ±SEM p value
Walking initiation (s) 2.54 1.98 0.96 ± 1.57 p = 0.3537
Ledge (/60s) 48.92 43.35 29.12 ± 19.79 p = 0.4315
Platform (/60s) 22.97 25.74 4.4 ± 18.55 p = 0.7294
Pole (/120s) 25.92 22.16 0.84 ± 25.07 p = 0.5844
Turn (/60s) 23.73 15.97 −1.79 ± 25.52 p = 0.5844
60 degree screen (/60s) 11.43 10.68 7.88 ± 3.54 p = 0.634
90 degree screen (/60s) 16.98 16.49 7.04 ± 9.93 p = 0.9049
Inverted screen (/60s) 49.92 41.10 32.17 ± 17.74 p = 0.1437
Fine movements (/1h) 1758 1549.00 209.1 ± 115.5 p = 0.0861
Total ambulations (/1h) 756.5 674.3 −82.20 ± 64.16 p = 0.2155
Time rearing (/hr) 688.5 583.3 105.1 ± 81.22 p = 0.2111
Center distance (mm/h) 4288 3941 347.4 ± 506.5 p = 0.5010
Center time (/1h) 478.3 557.6 −79.30 ± 112.8 p = 0.4905
Center entries (/1h) 263.9 236.1 27.81 ± 27.70 p = 0.3281
Total rest time (s/1 h) 1504 1635 −130.6 ± 118.7 p = 0.2847
Total ambulations over time 4539 4046 493.2 ± 385.0 p = 0.2733
Rearing frequency over time 116.8 123.5 6.671 ± 14.51 p = 0.8508
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Gq/11-driven UM tumor cells from patient biopsies of primary
ocular tumors with low or high metastatic potential and liver
metastases. And lastly, although FR does not discriminate
between wild-type and oncogenic Gq/11, and host Gq/11 ac-
tivity is physiologically essential, we were able to identify a
therapeutic window in which FR strongly inhibited tumor
growth without causing large negative effects on viability or
physiology. UM tumors therefore appear to be particularly
vulnerable to FR.
The vulnerability of UM tumors to FR may occur because
the signaling networks downstream of oncogenic Gq/11 must
be maintained above a high threshold. In support of this hy-
pothesis, we found that a therapeutically effective dose of FR
strongly inhibits UM tumor growth but only modestly reduces
oncogenic G11-driven Erk phosphorylation in UM tumors.
Because nearly complete inhibition of Erk phosphorylation by
FR was not necessary to inhibit UM tumor growth, Erk likely
cooperates with other signaling pathways downstream of
oncogenic Gq/11 (42) to sustain UM tumors. Indeed, Gq/11
and MEK inhibitors recently have been shown to synergize and
regress UM tumor xenografts (30), suggesting that synergism
might improve efficacy or safety of Gq/11 inhibitors such as FR
as therapeutic agents for UM.
Therapeutic implications
Our results suggest several ways that Gq/11 inhibitors such
as FR could be explored therapeutically to treat UM patients,
either alone or in conjunction with current standards of care.
Primary UM tumors usually are treated by external beam or
plaque irradiation of the eye (12) to arrest growth, induce
tumor cell death, and preserve vision, although these in-
terventions on their own do not improve prognosis for
Figure 6. FR inhibits growth of xenografted class 1 and class 2 UM tumors. A, tumor volume (upper panels) as a function of time and dose of FR
administered by s.c. injection of mice (n=9–11/group) on alternate days. Effect of FR on tumor weight (lower panels) measured in surviving mice at the end
of the experiment. B, effect of FR on Erk phosphorylation as a marker of oncogenic G11 signaling in MP41 cells in vitro versus tumors from animals treated
with vehicle or FR at the indicated doses. Shown are the effects of FR on pERK: total Erk ratios relative to vehicle controls (n = 3 independent cell cultures/
condition; n = 3 independent tumors/condition); data shown are representative of three independent determinations, each performed with three cell
culture and tumor replicates per condition. C, durability of MP41 tumor response to FR. MP41 tumor-bearing mice (n = 4) were treated systemically with FR
for 28 days, after which time FR treatment was stopped. Tumors resumed growth 16 days after FR treatment was withdrawn. Results shown are repre-
sentative of two independent experiments. Asterisks indicate p < 0.05 (t-test) in panels A and B.
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metastasis (13). Once metastatic UM occurs in the liver,
therapy involves mechanical isolation of the hepatic vascula-
ture by embolization and percutaneous infusion of high-dose
chemotherapeutics (43) or radiotherapy (44) above what
would be tolerated systemically (45). Thus, targeting delivery
of FR to primary UM tumors by intravitreal injection, or he-
patic metastases by chemoembolization, could be considered.
Targeted delivery might be required to reduce the impact of
FR on viability, blood pressure, or other dose-limiting physi-
ological processes, or allow FR to be delivered at higher doses
in an effort to promote durable arrest or tumor regression. If
FR proves to have limited efficacy in monotherapy, it could be
combined with standard-of-care interventions to treat primary
and metastatic UM. Intravitreal injection of FR also might
interfere with progression of very early-stage lesions to class 2
tumors that have high metastatic potential by promoting
melanocytic differentiation, as we have shown for class 1 UM
tumor cells ex vivo. Similarly, because intraocular nevi are
relatively common, express constitutively active Gq/11, and
can progress to early stage melanomas (46), intravitreal in-
jection of FR might interfere with this process and reduce the
incidence of UM.
UM is only one of several diseases that potentially could
benefit from targeted treatment with FR. Constitutively active
mutant forms of Gq/11 occur in 5% of all cancers, including
melanocytic neoplasms of the central nervous system (4),
mucosal melanoma (5), choroidal hemangiomas (8, 11), and
hepatic small vessel neoplasms (6), as well as in Sturge–Weber
syndrome (7), certain forms of hypercalcemia and hypocalce-
mia (9), and autosomal dominant hypoparathyroidism
(10). Treatment regimens for all of these conditions poten-




FR900359 (FR) was purified from Ardisia crenata according
to published methods (16). SRE.L assays used a firefly lucif-
erase reporter driven by the Gq/11-dependent SRE promoter
and were performed as described (47). Firefly luciferase activity
was normalized to Renilla luciferase expressed from a consti-
tutive promoter.
Cell culture assays
Cells were cultured at 37C in 5% CO2. Human 92.1
(RRID:CVCL_8607), Mel270 (RRID:CVCL_C302), and OCM-
1A (RRID:CVCL_6934) UM cells were derived by and the
generous gifts of Drs. Martine Jager (Laboratory of Ophthal-
mology, Leiden University), Bruce Ksander (Schepens Eye
Institute, Massachusetts Eye and Ear Infirmary), and June Kan-
Mitchell (Biological Sciences, University of Texas at El Paso),
respectively. The human PDX cell lines MP41 (ATCC Cat#
CRL-3297, RRID:CVCL_4D12) and MP46 (ATCC Cat# CRL-
3298, RRID:CVCL_4D13) cell lines were purchased from
ATCC (Manassas, VA). Cell lines were grown in RPMI 1640
medium (Life Technologies, Carlsbad, CA) supplemented with
FBS and antibiotics. Cell viability was measured using a water-
soluble tetrazolium salt, WTS-8 (Bimake, Houston, TX),
following the manufacturer’s protocol. Flow cytometry for
analysis of cell proliferation and apoptosis was performed at
the Siteman Cancer Center Flow Cytometry Core on a
FACScan analyzer (BD Biosciences, San Diego CA, USA) using
a standard propidium iodide staining protocol as described
previously (48).
Patients and biopsy collection
Human UM biopsy or enucleation samples were obtained
with patient written informed consent and with approval of the
institutional review board of Washington University in St
Louis. Fine-needle aspiration biopsies of primary UM tumors
and ultrasound-guided core biopsies of UM liver metastases
were performed as part of standard of care, which also
collected biopsies for cytological evaluation of tumor cells and
molecular classification (Castle Biosciences). For enucleation
samples, after excision, eyes were transilluminated to localize
the tumor mass and then opened opposite the tumor. Vitreous
was carefully removed and tumor samples were collected
through the retina from the tumor apex. All samples were
collected directly into growth medium in the operating room
before being transported to the laboratory. Primary uveal
melanoma cells were divided equally into two wells of
fibronectin-covered 6-well tissue culture plates and grown in
5% CO2 in MDMF medium, which consists of HAM’s F12
(Lonza, Walkersville MD, USA) supplemented with 1 mg/ml
BSA (Sigma-Aldrich, St Louis MO, USA), 2 mM L-glutamine
(Lonza), 1X SITE (Sigma-Aldrich), 1x B27 (Gibco, Carlsbad
CA, USA), 20 ng/ml bFGF (PeproTech Inc, Rocky Hill NJ,
USA), and 50 μg/ml Gentamicin (Sigma-Aldrich) (49). Cells
were allowed to attach to the substrate overnight before fresh
medium was added to each well containing either 100 nM FR
or an equal volume of vehicle (DMSO).
Bulk RNAseq
MP41 and MP46 cells were treated with 100 nM FR or
vehicle (DMSO) in RPMI growth medium and collected after
3 days of treatment. FNAB samples were treated with 100 nM
FR or vehicle in MDMF medium and collected after 7 days of
treatment. RNA was isolated using the RNeasy Mini Kit
(Qiagen) following the manufacturer’s protocol and including
the optional DNase I treatment step. RNA quality was assessed
on a Bioanalyzer 2100 (Agilent Technologies, Santa Clara, CA,
USA). mRNA was extracted from total RNA using a Dynal
mRNA Direct kit, fragmented, and reverse transcribed to
double-stranded cDNA with random primers before addition
of adapters for library preparation. Library preparation and
HiSeq2500 sequencing were performed by the Washington
University Genome Technology Access Center (gtac.wustl.
edu). FastQ files were aligned to the transcriptome and the
whole genome with STAR. Biologic replicates were simulta-
neously analyzed by edgeR and Sailfish analyses of gene-level/
exon-level features. Unexpressed genes and exons were
removed from the analyses. Unsupervised principal compo-
nent analysis was generated in Bioconductor using edgeR.
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Direct comparison of FR response in MP41 versus MP46 cells
was used to identify MP41-specific genes, and this list was used
as signature gene sets for Gene Set Enrichment Analysis
(GSEA) (50).
Single-cell RNAseq
Single-cell RNAseq (scRNAseq) was performed using the
10X Genomics platform. Single-cell suspensions were counted
using a hemocytometer and adjusted to 1000 cells/μl. Sample
processing through 10X Genomics and NextSeq 500 (Illu-
mina) sequencing was performed by the Washington Univer-
sity Genome Technology Access Center (gtac.wustl.edu). Raw
base call files were analyzed using Cell Ranger v.3.0.2. The
filtered counts data from all six samples were combined in
Partek Flow (www.partek.com). Samples were filtered on total
reads, detected features, and mitochondrial content per cell to
remove cell doublets and apoptotic debris. Unexpressed fea-
tures were removed, and samples were normalized and log
transformed.
PCA was used to reduce dimensionality, and the first 20
principal components were further analyzed by graph-based
(Louvain) clustering and t-SNE. The resulting 24 clusters
were visualized in a two-dimensional t-SNE representation
and were annotated to known biological cell types using ca-
nonical marker genes. The following cell types were annotated
(selected markers are listed): Lymphocytes (CD3D, CD3G,
IL7R); macrophages (C1QA, C1QB, C1QC); dendritic cells
(CD1C and lack of expression of C1QA, C1QB and C1QC);
retinal cells (SYNGR1, NPTX1); photoreceptors (GNAT1,
GNGT1); RPE(PAX6, KRT8, KRT18); melanoma (DCT,
TYRP1, PMEL).
Mice
All experiments were performed using the NOD scid
gamma (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ: NSG) mice pur-
chased from The Jackson Laboratory (#005557). All animal
experiments were performed under protocols approved by the
Animal Studies Committees of Washington University in St
Louis School of Medicine and Drexel University College of
Medicine. FR was prepared from a 15 mM stock solution in
DMSO at doses of 0.1, 0.3, 1.0, or 3.0 mg/kg and dextrose at a
final volume of 200 μl. FR was administered subcutaneously
every other day. Animals were randomly grouped (n = 10/
group) for placebo (1% DMSO) or FR treatments. MP41,
MP46, and OCM1A cells were inoculated subcutaneously into
the flanks of 5-week-old male NSG mice. Cells were prepared
at a concentration of 2 x 10⁶ cells/100 μl in a solution of ice-
cold PBS/Matrigel Matrix (50/50 v/v) (Fisher Scientific #
CB40234 A). Primary tumors were allowed to grow to
30 mm2 basal area based on measurements taken with cal-
ipers and using the formula (L × 2W)/2 where L and W are the
longest and the shortest basal diameters of the tumor,
respectively, before beginning treatment with FR. Tumors
reaching a maximum length of 2 cm were defined as censored
end points. At censored end points or at the end of each time
course, mice were euthanized, and the tumors were removed
using sterile surgical technique. Excised tumors were weighed
to determine end-point mass and snap-frozen in liquid ni-
trogen for later use.
Immunoblotting
For tumor samples, approximately 100 mg of tumor was
homogenized on ice in 1X Cell Lysis Buffer (Cell Signaling
Technology, catalog# 9803) supplemented with 1 mM PMSF.
For cultured cells, cells were grown in 10 cm dishes and
treated with DMSO or 1 μM FR for 18 h, and then lysed in 1X
Cell Lysis Buffer. Lysates were sonicated on ice for 2 min (30 s
on, 30 s off, 60% A), rotated end-over-end for 30 min, and
cleared by centrifugation at 16,000 × g for 15 min. Protein
concentration was determined using Bio-Rad Protein Assay
Dye Reagent (Bio-Rad, catalog# 5000006). In total, 15 μg of
tumor protein was resolved on 12% SDS-PAGE gels and
transferred to Immobilon-FL PVDF membrane (Millipore,
catalog# IPFL00010). Membranes were blocked with 5% (w/v)
BSA in TBST [20 mM Tris pH 7.6, 137 mM NaCl, 0.1% v/v
Tween 20] and incubated with primary antibodies [Phospho-
p44/42 MAPK (Erk1/2) Cell Signaling Technology, catalog#
4370S lot#24 and p44/42 MAPK (Erk1/2) Cell Signaling
Technology catalog# 9107S lot#10]. Membranes were
washed with TBST at least three times and incubated with
IRDye 680–coupled goat anti-rabbit (LI-COR, catalog#
926–68,071, lot# C90618–09) and IRDye 800 goat anti-mouse
(LI-COR, catalog# 926–32,210, lot# C91210–09 antibodies
(LI-COR Biosciences). After incubation, membranes were
washed at least three times with TBST, and signals were
detected using Odyssey model 9120 imaging system (LI-COR
Biosciences).
Mouse radiotelemetry
Blood pressure and heart rate responses to chronic admin-
istration of vehicle or FR900359 were monitored by radiote-
lemetry in conscious mice by following previously described
procedures (24, 51). Briefly, adult NSG male mice were
implanted with a radiotelemetry pressure-sensing catheter in
the right carotid artery under isoflurane (3% mixed with 95%
oxygen) anesthesia. The body of the transmitter (HD-X10,
Data Science International (DSI), St Paul, MN) was tunneled
into a subcutaneous pouch on the left flank of the animal. The
mice were allowed to recover from the surgery for 1 week after
which baseline blood pressure and heart rate were recorded for
24 h, followed by alternating days of subcutaneous adminis-
tration of vehicle or FR. After the 24-h baseline recordings, the
mice were randomly assigned to two groups: one group
receiving FR (0.3 mg/kg in dextrose, s.c.) and the other group
receiving equal amounts of vehicle (2 μl DMSO in 200 μl of 5%
dextrose, s.c.). Daily recordings were conducted from 1 to 5
PM for 14 days, and FR or vehicle was administered every
other day at 3 PM. Continuous 24-h BP recordings were
conducted during the first injection and seventh injection of
FR. Data was acquired and analyzed using DSI Ponemah
software version 6.5. Averages of continuous systolic blood
pressure (SBP), diastolic blood pressure (DBP), mean blood
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pressure (MBP), and heart rate (HR) recordings were plotted
in 1 h intervals over 24 h.
Mouse behavioral tests
Mice were moved to the animal facility and allowed to
acclimate to the new environment for 1 week prior to
behavioral testing. All behavioral testing was conducted during
the light cycle, by a female experimenter blinded to experi-
mental group. All equipment was cleaned with 2% chlorhexi-
dine diacetate or 70% ethanol between animals.
Open-field activity/exploratory behavior
General activity levels and exploratory behavior were
quantified over a 60-min period in an open field (47.6 cm L x
25.4 cm W x 20.6 cm H) constructed of Plexiglas and sur-
rounded by computerized photobeam instrumentation (Kinder
Scientific, LLC, Poway, CA). General activity variables (total
ambulations, rearings, time at rest) along with measures of
emotionality, including time spent, distance traveled, and en-
tries made into the central zone, were analyzed.
Sensorimotor battery
Walking initiation, ledge, platform, pole, and inclined and
inverted screen tests were performed as previously described
(52). Time in each task was manually recorded. The average of
two trials was used for analyses. Test duration was 60 s, except
for the pole test, which was extended to 120 s. For walking
initiation, time for an animal to leave a 21 x 21 cm2 square on a
flat surface was recorded. For ledge and platform tests, the
time the animal was able to balance on an acrylic ledge
(0.75 cm wide and 30 cm high), and on a wooden platform
(1.0 cm thick, 3.0 cm in diameter and elevated 47 cm), was
recorded, respectively. The pole test was used to evaluate fine
motor coordination by quantifying time to turn 180 and
climb down a vertical pole. The screen tests assessed a com-
bination of coordination and strength by quantifying time to
climb up or hang onto a mesh wire grid measuring 16 squares
per 10 cm, elevated 47 cm and inclined (60 or 90) or
inverted.
Statistical analyses
All statistical analyses were performed using IBM SPSS
software (v.24) and Graphpad Prism 8. For cell line data, all
experiments were performed in triplicate at least three times
on different days. Means and standard errors were computed
from all cell line data and t-tests were used to determine sig-
nificance. For significance analysis of PCA data, correlation of
each principal component with FR treatment was calculated
using paired t-tests with Holm–Sídák correction for multiple
comparisons. For behavioral studies, all data were screened for
fit of distributions with assumptions underlying univariate
analyses, which included the Shapiro–Wilk test and q-q plot
investigations for normality. Means and standard errors were
computed for each measure. Repeated measures analysis of
variance (ANOVA) and independent samples t-tests were used
to analyze behavioral data. Statistical results were confirmed
with two-tailed nonparametric testing, when available, for any
data sets with violations of the univariate assumptions. Prob-
ability value for all analyses was p < 0.05, unless otherwise
stated.
Data availability
All RNAseq and single-cell RNAseq data have been
deposited on the NCBI GEO server with the accession
#GSE165552. All other data associated with this study are
presented in the main text or supplementary materials.
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